Idera Pharmaceuticals (IDRA) and Merck (MRK) Extend Research Collaboration for 1-Yr
More News related to IDRA
- Idera Pharma (IDRA) Issues Update on Drug Candidate Pipeline Target to Toll-Like Receptors
- Idera Pharmaceuticals Provides Update on Drug Candidate Pipeline Targeted to Toll-like Receptors
- Idera Pharmaceuticals Announces Presentations of Preclinical Data on Modulation of Toll-like Receptors 3, 7, and 9 through Antisense
- Idera Pharmaceuticals to Present at Noble Financial Capital Market's Fifth Annual Equity Conference
- Idera Pharmaceuticals to Present at BIO Business Forum and Participate in Panel at BIO 2009
More News related to MRK
- National BDPA and WorkplaceDiversity.com Announce Winners of the 2009 Best Companies for Blacks in Technology Award
- Merck Prices $4.25 Billion Debt Offering
- Notable Mergers and Acquisitions of the Day 6/22: TWGP/SUAI, MRK/SGP, AAUK
- Vical (VICL) Receives $1.5M Milestone Payment from Merck (MRK)
- Merck (MRK) and Schering-Plough (SGP) Receives FTC "Second Request" for Additional Information On Merger
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that Merck & Co., Inc. (NYSE: MRK) has extended its research collaboration with Idera for an additional year. The Company and Merck entered into an exclusive license and research collaboration agreement to research, develop and commercialize vaccine products containing the Company's investigational agonist compounds targeting Toll-like Receptors 7, 8, and 9 in the fields of oncology, infectious diseases and Alzheimer's disease in December 2006. As part of the agreement, the two companies engaged in a two-year research collaboration to generate novel agonists targeting TLR7 and TLR8 incorporating both Merck and Idera chemistry for use in the licensed fields.
Idera Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of DNA- and RNA-based compounds for the treatment of infectious diseases, autoimmune diseases, cancer, and asthma and allergies and for use as vaccine adjuvants.
Related Categories
Corporate NewsStocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
